Published in Blood Weekly, August 27th, 2009
"Although for acute AMRs, therapy mainly relies on plasmapheresis or immunoadsorption, 110 studies for treatment of chronic AMR are available. Here, we report on four kidney allograft recipients suffering from chronic AMR I to 27 years posttransplant, who were treated with a combination of rituximab and intravenous immunoglobulin (IVIG). Rituximab/IVIG improved kidney...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.